Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00588146 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia
A Phase 2 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00588146: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT00588146 is a Phase 2 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00588146, a Phase 2 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and tolerability of pegylated interferon alpha-2b (PEG-Intron) in patients with severe complications related to Hereditary hemorrhagic telangiectasia (HHT). Funding Source - FDA Office of Orphan Products Development (OOPD)
Interventions
- OTHER Standard care
- DRUG Pegylated Interferon Alpha2b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-01 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00588146
The ClinicalTrials.gov registry entry for NCT00588146 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard care is the first listed.
NCT00588146 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00588146 about?
NCT00588146 is a clinical study titled "Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia". The purpose of the study is to evaluate the safety and tolerability of pegylated interferon alpha-2b (PEG-Intron) in patients with severe complications related to Hereditary hemorrhagic telangiectasia (HHT). Funding Source - FDA Office of Orphan Products Development (OOPD)
What is the current status of trial NCT00588146?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2007-01. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00588146?
The interventions under investigation include: Standard care (OTHER), Pegylated Interferon Alpha2b (DRUG).
Who is sponsoring clinical trial NCT00588146?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.